1. Scrip
  2. >>Therapy Areas

Innate pockets $35 million from BMS for Phase I anticancer antibody

 
• By Sukaina Virji

Innate Pharma is to receive $35 million up front having secured a global agreement for the development and commercialisation of IPH2102, a novel antibody in Phase I to treat cancer, with Bristol-Myers Squibb.

Innate Pharma is to receive $35 million up front having secured a global agreement for the development and commercialisation of IPH2102, a novel antibody in Phase I to treat cancer, with Bristol-Myers Squibb.

The product is still up to two years away from Phase II testing, Innate's senior financial advisor Catherine Moukheibir (former...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By Manas Mishra

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.